159 related articles for article (PubMed ID: 28314118)
1. In Vitro Assay Development and HTS of Small-Molecule Human ABAD/17β-HSD10 Inhibitors as Therapeutics in Alzheimer's Disease.
Aitken L; Baillie G; Pannifer A; Morrison A; Jones PS; Smith TK; McElroy SP; Gunn-Moore FJ
SLAS Discov; 2017 Jul; 22(6):676-685. PubMed ID: 28314118
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Hroch L; Benek O; Guest P; Aitken L; Soukup O; Janockova J; Musil K; Dohnal V; Dolezal R; Kuca K; Smith TK; Gunn-Moore F; Musilek K
Bioorg Med Chem Lett; 2016 Aug; 26(15):3675-8. PubMed ID: 27287370
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment.
Hroch L; Guest P; Benek O; Soukup O; Janockova J; Dolezal R; Kuca K; Aitken L; Smith TK; Gunn-Moore F; Zala D; Ramsay RR; Musilek K
Bioorg Med Chem; 2017 Feb; 25(3):1143-1152. PubMed ID: 28082069
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.
Morsy A; Trippier PC
J Med Chem; 2019 May; 62(9):4252-4264. PubMed ID: 30444369
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics.
Kissinger CR; Rejto PA; Pelletier LA; Thomson JA; Showalter RE; Abreo MA; Agree CS; Margosiak S; Meng JJ; Aust RM; Vanderpool D; Li B; Tempczyk-Russell A; Villafranca JE
J Mol Biol; 2004 Sep; 342(3):943-52. PubMed ID: 15342248
[TBL] [Abstract][Full Text] [Related]
6. Infantile Neurodegeneration Results from Mutants of 17β-Hydroxysteroid Dehydrogenase Type 10 Rather Than Aβ-Binding Alcohol Dehydrogenase.
He XY; Dobkin C; Brown WT; Yang SY
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239833
[TBL] [Abstract][Full Text] [Related]
7. Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction.
Valaasani KR; Sun Q; Hu G; Li J; Du F; Guo Y; Carlson EA; Gan X; Yan SS
Curr Alzheimer Res; 2014 Feb; 11(2):128-36. PubMed ID: 24479630
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease.
Yao J; Du H; Yan S; Fang F; Wang C; Lue LF; Guo L; Chen D; Stern DM; Gunn Moore FJ; Xi Chen J; Arancio O; Yan SS
J Neurosci; 2011 Feb; 31(6):2313-20. PubMed ID: 21307267
[TBL] [Abstract][Full Text] [Related]
9. 3-Hydroxyacyl-CoA and Alcohol Dehydrogenase Activities of Mitochondrial Type 10 17β-Hydroxysteroid Dehydrogenase in Neurodegeneration Study.
He XY; Dobkin C; Brown WT; Yang SY
J Alzheimers Dis; 2022; 88(4):1487-1497. PubMed ID: 35786658
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.
Lim YA; Grimm A; Giese M; Mensah-Nyagan AG; Villafranca JE; Ittner LM; Eckert A; Götz J
PLoS One; 2011; 6(12):e28887. PubMed ID: 22174920
[TBL] [Abstract][Full Text] [Related]
11. Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17β-HSD10 with Implications to Alzheimer's Disease Treatment.
Schmidt M; Benek O; Vinklarova L; Hrabinova M; Zemanova L; Chribek M; Kralova V; Hroch L; Dolezal R; Lycka A; Prchal L; Jun D; Aitken L; Gunn-Moore F; Kuca K; Musilek K
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192199
[TBL] [Abstract][Full Text] [Related]
12. ABAD: a potential therapeutic target for Abeta-induced mitochondrial dysfunction in Alzheimer's disease.
Marques AT; Fernandes PA; Ramos MJ
Mini Rev Med Chem; 2009 Jul; 9(8):1002-8. PubMed ID: 19601895
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Aβ for treatment of Alzheimer's disease.
Valasani KR; Hu G; Chaney MO; Yan SS
Chem Biol Drug Des; 2013 Feb; 81(2):238-49. PubMed ID: 23039767
[TBL] [Abstract][Full Text] [Related]
14. Determination of small molecule ABAD inhibitors crossing blood-brain barrier and pharmacokinetics.
Vangavaragu JR; Valasani KR; Fang D; Williams TD; Yan SS
J Alzheimers Dis; 2014; 42(1):333-44. PubMed ID: 24858403
[TBL] [Abstract][Full Text] [Related]
15. [Mitochondrial enzyme ABAD and its role in the development and treatment of Alzheimer's disease].
Benek O; Musílek K; Kuca K
Ceska Slov Farm; 2012 Aug; 61(4):144-9. PubMed ID: 23251955
[TBL] [Abstract][Full Text] [Related]
16. Roles of Mitochondrial 17β-Hydroxysteroid Dehydrogenase Type 10 in Alzheimer's Disease.
He XY; Isaacs C; Yang SY
J Alzheimers Dis; 2018; 62(2):665-673. PubMed ID: 29480196
[TBL] [Abstract][Full Text] [Related]
17. Methylene Blue Improves Brain Mitochondrial ABAD Functions and Decreases Aβ in a Neuroinflammatory Alzheimer's Disease Mouse Model.
Zakaria A; Hamdi N; Abdel-Kader RM
Mol Neurobiol; 2016 Mar; 53(2):1220-1228. PubMed ID: 25601181
[TBL] [Abstract][Full Text] [Related]
18. ABAD/17β-HSD10 reduction contributes to the protective mechanism of huperzine a on the cerebral mitochondrial function in APP/PS1 mice.
Xiao X; Chen Q; Zhu X; Wang Y
Neurobiol Aging; 2019 Sep; 81():77-87. PubMed ID: 31252207
[TBL] [Abstract][Full Text] [Related]
19. 6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17β-HSD10 and potential drugs for Alzheimer's disease treatment: Design, synthesis and in vitro evaluation.
Benek O; Hroch L; Aitken L; Dolezal R; Guest P; Benkova M; Soukup O; Musil K; Kuca K; Smith TK; Gunn-Moore F; Musilek K
Med Chem; 2017 Jan; ():. PubMed ID: 28067167
[TBL] [Abstract][Full Text] [Related]
20. Novel Benzothiazole-based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer's Disease Treatment.
Aitken L; Benek O; McKelvie BE; Hughes RE; Hroch L; Schmidt M; Major LL; Vinklarova L; Kuca K; Smith TK; Musilek K; Gunn-Moore FJ
Molecules; 2019 Jul; 24(15):. PubMed ID: 31362457
[No Abstract] [Full Text] [Related]
[Next] [New Search]
